Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability.
Shinya NakataniEiji IshimuraYuri MachibaAyumi NakataniKenta FujimotoHideki UedonoYujiro OkuteAkihiro TsudaKatsuhito MoriMasanori EmotoMasaaki InabaPublished in: Nephrology (Carlton, Vic.) (2019)